News
Novo Seeks US, EU Approval for Etavopivat in Sickle Cell Disease
If approved, Novo’s etavopivat could offer a new disease-modifying treatment approach for people living with sickle cell disease.
E-MAIL: support@healthxploreindia.com
E-MAIL: healthxploreindia@gmail.com
If approved, Novo’s etavopivat could offer a new disease-modifying treatment approach for people living with sickle cell disease.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
